Analyst Reco. Boston Scientific Corporation

Equities

BSX

US1011371077

Advanced Medical Equipment & Technology

Delayed Nyse Other stock markets 21:00:02 16/01/2026 GMT			5-day change	1st Jan Change
88.07 ^USD	-2.18%		-9.80%	-7.64%

01-16	Oppenheimer Adjusts Price Target on Boston Scientific to $100 From $125, Maintains Outperform Rating	MT
01-16	RTW Biotech's portfolio firm Penumbra acquired by Boston Scientific	AN

Analyst Reco.

01-16	Oppenheimer Adjusts Price Target on Boston Scientific to $100 From $125, Maintains Outperform Rating	MT
01-15	Sector Update: Health Care Stocks Softer Late Afternoon	MT
01-09	Goldman Sachs Adjusts Price Target on Boston Scientific to $112 From $124, Maintains Buy Rating	MT
01-06	Evercore ISI Adjusts Price Target on Boston Scientific to $112 From $113, Maintains Outperform Rating	MT
12-18	Truist Securities Adjusts Price Target on Boston Scientific to $120 From $130, Maintains Buy Rating	MT
12-17	RBC Adjusts Price Target on Boston Scientific to $130 From $125, Maintains Outperform Rating	MT
12-17	Canaccord Genuity Adjusts PT on Boston Scientific to $131 From $132, Maintains Buy Rating	MT
12-16	Baird Adjusts Price Target on Boston Scientific to $118 From $132, Maintains Outperform Rating	MT
12-08	Analyst recommendations: 3M Company, Exxon Mobil, Mastercard, Netflix, Tesla…
28/10/25	Daiwa Securities Adjusts Price Target on Boston Scientific to $124 From $121, Maintains Buy Rating	MT
23/10/25	UBS Adjusts Boston Scientific Price Target to $140 From $135, Maintains Buy Rating	MT
23/10/25	Wells Fargo Adjusts Price Target on Boston Scientific to $125 From $124, Maintains Overweight Rating	MT
23/10/25	Morgan Stanley Adjusts PT on Boston Scientific to $130 From $125, Maintains Overweight Rating	MT
23/10/25	Leerink Partners Adjusts PT on Boston Scientific to $130 From $128, Maintains Outperform Rating	MT
23/10/25	Baird Adjusts Price Target on Boston Scientific to $132 From $128, Maintains Outperform Rating	MT
23/10/25	Jefferies Adjusts Price Target on Boston Scientific to $132 From $130, Maintains Buy Rating	MT
23/10/25	Goldman Sachs Adjusts Price Target on Boston Scientific to $124 From $120, Maintains Buy Rating	MT
23/10/25	Rothschild & Co Redburn Adjusts PT on Boston Scientific to $130 From $125, Maintains Buy Rating	MT
22/10/25	Wells Fargo Raises Price Target on Boston Scientific to $125 From $124, Maintains Overweight Rating	MT
22/10/25	Evercore ISI Adjusts Boston Scientific Price Target to $113 From $110	MT
22/10/25	Piper Sandler Adjusts Boston Scientific Price Target to $120 From $115	MT
22/10/25	Medical device maker Boston Scientific beats Q3 revenue estimates on strong US demand	RE
07/10/25	Evercore ISI Adjusts Boston Scientific Price Target to $110 From $115, Maintains Outperform Rating	MT
01/10/25	Barclays Adjusts Boston Scientific Price Target to $136 From $133, Maintains Overweight Rating	MT
01/10/25	Leerink Partners Adjusts Price Target on Boston Scientific to $128 From $127, Maintains Outperform Rating	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Boston Scientific exceeds analysts' estimates for seven straight quarters

June 26, 2025 at 10:04 am